ProPhase Labs Interest Expense 2011-2026 | PRPH

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense ProPhase Labs

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
764 K	1.15 M	295 K	-	167 K	54 K	213 K	18 K	10 K	13 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.15 M	10 K	298 K

Quarterly Interest Expense ProPhase Labs

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-45 K	-	-	30 K	-18 K	-	-33 K	8 K	215 K	-	201 K	201 K	233 K	-	296 K	323 K	251 K	-	41 K	-	-	-	-	-	-	-	15 K	4 K	96 K	-	125 K	151 K	54 K	-	53 K	53 K	52 K	-	1 K	1 K	1 K	-	1 K	1 K	2 K	-	3 K	2 K	3 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
323 K	-45 K	74.9 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
China Pharma Holdings CPHI	27.4 K	$ 0.63	-	$ 11 M	China
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	-	-	$ 2.06 B	France
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
Emergent BioSolutions EBS	87.9 M	$ 8.04	-0.12 %	$ 412 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Cumberland Pharmaceuticals CPIX	606 K	$ 3.18	4.1 %	$ 44.7 M	USA
Pacira BioSciences PCRX	-373 K	$ 22.82	0.75 %	$ 1.06 B	USA
Bausch Health Companies BHC	-28 M	$ 4.97	-2.55 %	$ 1.81 B	Canada
Harrow Health HROW	47 K	$ 35.03	3.03 %	$ 1.29 B	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
Evolus EOLS	-539 K	$ 4.43	-5.45 %	$ 286 M	USA
Rockwell Medical RMTI	2.3 M	$ 1.04	1.96 %	$ 24.3 M	USA
SCYNEXIS SCYX	3.13 M	$ 0.87	-0.29 %	$ 43.4 M	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Solid Biosciences SLDB	824 K	$ 6.69	-6.3 %	$ 585 M	USA
Sundial Growers SNDL	81 K	$ 1.36	-0.37 %	$ 3.37 M	Canada
Sonoma Pharmaceuticals SNOA	-10 K	$ 2.34	-8.24 %	$ 2.9 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 6.01	2.56 %	$ 237 M	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Tilray TLRY	46.6 M	$ 6.57	1.86 %	$ 4.06 B	Canada
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
TherapeuticsMD TXMD	300 K	$ 2.28	-1.2 %	$ 23.8 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Veru VERU	862 K	$ 2.28	-0.87 %	$ 308 M	USA
Viatris VTRS	573 M	$ 13.43	1.02 %	$ 16.1 B	USA
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
cbdMD YCBD	-29.5 K	$ 0.78	1.3 %	$ 3.36 M	USA
Organogenesis Holdings ORGO	20 K	$ 2.43	-1.62 %	$ 320 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Perrigo Company plc PRGO	-13.2 M	$ 9.65	0.89 %	$ 1.34 B	USA
Canopy Growth Corporation CGC	74.6 M	$ 0.94	-2.32 %	$ 101 M	Canada
Assertio Holdings ASRT	2.78 M	$ 15.95	13.93 %	$ 102 M	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
Zynerba Pharmaceuticals ZYNE	80.2 K	-	-	$ 55.5 M	USA